One important feature of human solid tumors is the presence of a hypoxic microenvironment. Under hypoxia, genes that contain a hypoxia-response element (HRE) can be activated by the binding of hypoxia-inducible factor-1. To reach the goal of selectively killing tumor cells in a hypoxic microenvironment using a gene therapy approach, we developed a cytosine deaminase (CD) gene construct (pH9YCD2) that contains an HRE gene enhancer. CD is an enzyme that catalyzes the conversion of noncytotoxic 5-fluorocytosine (5-FC) to the cytotoxic and radiosensitizing drug 5-fluorouracil (5-FU). Yeast CD was cloned into an SV40 promoterbased mammalian expression vector, and an HRE enhancer was inserted in front of the promoter. Human glioblastoma U-87 MG cells were transfected with pH9YCD2. Western blots revealed that CD was strongly expressed under hypoxic conditions (0.3-1% O 2 ), whereas only minor CD expression was seen under normoxic conditions. To confirm that the expressed CD enzyme retains catalytic activity, we performed a 5-FC/5-FU-conversion assay in which 5-FC was incubated with the lysates of pH9YCD2-transfected cells. The percentage of conversion from 5-FC to 5-FU was 63% under hypoxia versus 13% under normoxia. In vitro, cell viability and colony-forming efficiency assays demonstrated that the gene construct was able to significantly kill glioblastoma cells in a hypoxia-dependent manner. In addition, 5-FC treatment of hypoxic pH9YCD2-transfected cells produced a marked bystander effect, which could be a distinct advantage for gene therapy. If this construct exhibits antitumor efficacy in vivo, it may have promise as an antitumor agent in humans.
I n solid tumors, oxygen delivery to the respiring neoplastic and stromal cells is frequently reduced or even abolished by deteriorating diffusion geometry, severe structural abnormalities of tumor microvessels, and disturbed microcirculation. 1 In addition, anemia and the formation of methemoglobin or carboxyhemoglobin reduce the blood's capacity to transport O 2 . Thus, regions of very low oxygen partial pressures (hypoxia) occur either acutely or chronically in solid tumors. 2 Both highgrade intrinsic and metastatic brain tumors exhibit significant regions of hypoxia. 3 Kayama et al 4 reported that the simultaneously measured intratumoral pO 2 was 15.3 mmHg compared with 59.8 mmHg in brain cortex surrounding the brain tumors. This hypoxic tumor microenvironment can upregulate transcription of a wide range of genes, including genes involved in activating angiogenesis and glycolysis. 5 These responses to hypoxia can therefore support tumor growth and metastasis. In addition, hypoxia in tumors confers resistance to standard radiotherapy and chemotherapy. 6, 7 In brief, hypoxia is an important feature of solid tumors and most likely contributes to a poor therapeutic outcome regardless of which treatment is used. 8 A transcription factor, hypoxia-inducible factor-1 (HIF-1), plays an essential role in oxygen homeostasis. 9 HIF-1 recognizes and binds to hypoxia response elements (HREs), which act as enhancers for the transcription of hypoxia-inducible genes. Many of these genes have been identified, including vascular endothelial cell growth factor (VEGF), various glycolytic enzymes, and various glucose transporters. 10 VEGF is an angiogenesis factor that activates the biological activities of vascular endothelial cells. 11 The glycolytic enzymes and glucose transporters are important for glucose metabolism. In tumors, these hypoxia-inducible genes play major roles in tumor angiogenesis and tumor glucose metabolic adaptation. 12, 13 HIF-1 is a heterodimeric protein consisting of HIF-1a and HIF-1b. 10 HIF-1a is maintained at low levels in most cells under normoxic conditions because of the downregulatory effect of ubiquitination and proteosomal degradation. [14] [15] [16] However, under hypoxic conditions, HIF-1a is not targeted for downregulation because HIF1a hydroxylase, which requires dioxygen, is inactive. 5 Therefore, HIF-1a is stabilized and its level in the cell becomes markedly elevated. Elevated levels of HIF-1a have been demonstrated in a variety of human cancers, 17, 18 suggesting that HIF-1 plays an important role in mediating molecular response to hypoxia in tumors. 12, 19, 10 Since hypoxia is an important feature of solid tumors, including brain tumors, and because this leads to elevated HIF-1a, a potential therapeutic strategy for targeting hypoxic tumor cells is to introduce hypoxiaregulated suicide genes. Such genes should be able to selectively kill hypoxic tumor cells while sparing nonhypoxic normal cells.
We previously reported the development of a hypoxiaregulated Bax gene construct that contained HRE as the enhancer for the SV40 promoter. 20 Bax is a proapoptotic protein of the Bcl-2 family that induces apoptotic cell death in vitro and in vivo. [21] [22] [23] We demonstrated that the hypoxia-regulated Bax gene construct could trigger cell apoptosis under anoxic or hypoxic conditions. 20 To explore hypoxia-regulated gene therapy using other genes, we have constructed and evaluated a hypoxia-regulated yeast cytosine deaminase (CD) vector. CD is a nonmammalian enzyme that has been found in bacteria and yeast. 24 CD catalyzes the conversion of a relatively nontoxic pyrimidine derivative, 5-fluorocytosine (5-FC), to the highly potent chemotherapeutic agent 5-fluorouracil (5-FU). 24, 25 We chose yeast CD for our vector, because it is efficient in converting 5-FC into 5-FU, 26 and the superiority of yeast CD over bacterial CD for gene therapy in colon xenografts has been demonstrated. 27 5-FU is commonly used for cancer chemotherapy, and it can also enhance the response of tumor cells to radiation therapy. 28 However, the efficacy of systemic treatment with 5-FU is limited by gastrointestinal and hematological toxicities. 29 Dachs et al 30 used a three-copy HRE and PGK promoter-controlled gene construct to preferentially express bacterial CD in HT1080 fibrosarcoma cells under anoxic conditions, showing a 6.8-fold induction as compared to aerobic cells. The transfected cells also were more sensitive to 5-FC treatment under anoxia, exhibiting IC 50 values of 34 and 6.3 mM 5-FC for aerobic and anoxic conditions, respectively.
Our goal in developing a hypoxia-regulated CD gene vector is to selectively kill hypoxic brain tumor cells during radiation therapy, which preferentially kills aerobic cells, with the intent of improving the overall radioresponse of the tumor cells. As pointed out by Wouters and Brown, 31 cells exist under various amounts of oxygenation, and anoxic cells are the ones that die due to the lack of oxygen and nutrients and form necrotic regions within tumors. It is the cells at intermediate oxygen concentrations that are not killed due to their adaptation to nutrient deprivation, but they are also more resistant to radiation than aerobic cells. Therefore, it is these hypoxic cells that we wish to target and kill with gene therapy.
In this study, we have evaluated our CD vector, in which yeast CD expression is controlled by a nine-copy HRE and SV40 promoter, in human glioblastoma cells. We show that CD expression is markedly increased and it efficiently converted 5-FC to 5-FU under hypoxic condition. Moreover, cells transfected with the CD vector are killed by exogenous 5-FC, and there is a significant bystander effect in hypoxic cells.
Results

Hypoxia-activated CD expression in U-87 MG
Western blot analysis showed that pH9YCD2-transfected U-87 MG cells strongly expressed CD protein. Under hypoxic conditions (0.3% O 2 for 16 hours), CD was strongly expressed in the transiently (Fig 1a) or stably transfected cells (Fig 1b) . Compared to normoxic conditions, CD expression under hypoxia was about 37-fold higher in transiently transfected cells and about 25-fold higher in stably transfected cells. The positive control vector pZYCD, which lacks an HRE enhancer, expressed CD at similar levels under hypoxic and normoxic conditions (Fig 1a) . The negative control vector pH9LacZ exhibited no CD expression under hypoxia or normoxia (data not shown). A time course for CD expression in cells stably transfected with pH9YCD2 was performed by incubating Y87-1 (a stably transfected U-87 MG clone) cells under hypoxia for up to 72 hours (Fig 1c) . Yeast CD was barely detectable at 0 hours, but beginning at 4 hours the amount of CD was increased, and the level of CD increased with increasing incubation times. Figure 2 shows that pH9YCD2-transfected cells appeared to convert 65% of 5-FC to 5-FU under hypoxic conditions, whereas only 19% of 5-FC was converted under normoxic conditions. When these values were corrected by subtracting the nonspecific reaction background, that is, the radioactive count of pH9LacZ-transfected cells, we determined that under hypoxia, pH9YCD2-transfected cells converted 63% of 5-FC under the reaction conditions (producing a final 5-FC concentration of 1 mM). In contrast, under normoxia, only 13% of the 5-FC was converted to 5-FU. Untransfected control cells showed low nonspecific background under both hypoxic and normoxic conditions. Cells transfected with the positive-control vector pZYCD exhibited strong and equal conversion activity under hypoxic and normoxic conditions.
Hypoxia-activated CD expression produced significant cell killing with 5-FC treatment
Since Western blots and the CD activity assay revealed marked CD expression and catalytic activity in pH9YCD2-transfected cells under hypoxia, we investigated the killing effect of the vector on U-87 MG cells using two assays: Titer-Bluet cell viability and colonyforming efficiency (CFE). To determine the concentration of 5-FC to use in these assays, we first assayed the response of parent U-87 MG cells to 5-FC and 5-FU using the cell viability assay (Fig 3) . Concentrations as high as 4 mM of 5-FC did not produce significant inhibition of cell growth, whereas most of the cells were killed by 250 mM 5-FU. Thus, 1 mM 5-FC was chosen for testing pH9YCD2-transfected cells in subsequent studies.
As demonstrated by the cell viability assay, pH9YCD2 produced preferential killing in transiently transfected cells that were incubated with 1 mM 5-FC for 9 days (including an initial 48-hour hypoxic incubation period) (Fig 4) . Only 26% of these cells were viable, whereas 60% of 5-FC treated cells remained viable under normoxic conditions (without the initial 48-hour hypoxic incubation period). 5-FC produced only a minor effect on the viability of negative control vector pH9LacZ-transfected cells; 93% of these cells remained viable under both hypoxic and normoxic conditions. The positive control vector pZYCD showed strong and equal cell killing effects under hypoxic and normoxic conditions; only 18% of 5-FC-treated cells were viable. The viability of pH9YCD2-transfected cells under normoxia was lower than that of negative control vector (pH9LacZ)-transfected cells, suggesting that pH9YCD2 produced a small amount of CD under normoxia.
The CFE assay is able to determine cellular reproductive integrity by defining the surviving fraction of the seeded cells that grow into colonies. When U-87 MG clones stably transfected with pH9YCD2 (Y87-1 and Y87-2) were treated with 5-FC under hypoxic conditions and analyzed for CFE, the two clones showed marked lower surviving fractions than when treated under normoxic conditions (Fig 5) . Survival varied with 5-FC concentration and with the duration of hypoxic incubation. When treated with 500 mM 5-FC for 72 hours, both hypoxic Y87-1 and Y87-2 cells exhibited surviving fractions that were more than 2 log scales lower than those of the corresponding normoxic cells. Normoxic Y87-1 and Y87-2 cells also showed a small toxic response to 5-FC, perhaps an indication of low levels of CD production under normoxia, which varied depending on Hypoxia-activated CD expression produced a significant bystander effect
We mixed different percentages of pH9YCD2 stably transfected U-87 MG cells (Y87-1 or Y87-2) with parental cells, cocultured the mixture with 5-FC under hypoxia for 0, 24, or 48 hours, then continued incubation under normoxic condition for a total of 9 days including the initial hypoxic incubation. The expected cell viabilities (as measured by fluorescence) for the mixtures were calculated as the percent of Y87-1 cells in the mixture times the viability of the 100% Y87-1 control group plus the percent of U-87 MG cells in the mixture times the viability of the 100% U-87 MG control group. As shown in Figure 6 , under hypoxia, the observed cell viability was only 41% of the expected cell viability in the mixture composed of 25% Y87-1 cells and 75% U-87 MG cells and incubated under hypoxia for 48 hours. A bystander effect, in which the observed viability was lower than the expected viability also occurred in the 50% Y87-1/50% U-87 MG and 75% Y87-1/25% U-87 MG mixtures that were hypoxic for 48 hours. A bystander effect also occurred when cells were hypoxic for 24 hours; however, the magnitude of the effect appears to be lower than that seen for the 48-hour hypoxic periods. Mixtures of Y87-2 cells and U-87 MG cells produced similar bystander effects (data not shown).
Discussion
Our efforts are focused on improving the outcome of radiation therapy in brain tumor patients. Since human brain tumors contain hypoxic cells, 3 and because hypoxic cells are known to be resistant to radiation, 6 we believe one way to improve radiation therapy is to concomitantly administer a therapy that selectively kills hypoxic cells. This type of therapy should target tumor, because hypoxia is a feature of tumor tissue and not normal brain tissue. 
Gene-directed prodrug cancer therapy D Wang et al
We have centered our efforts on developing a gene therapy strategy that capitalizes on the hypoxia in tumors to activate expression of a suicide gene. HIF-1a, which is elevated in tumor by hypoxia, binds to the HRE of hypoxia-response genes and enhances their expression. There have been a number of reports demonstrating the approach of hypoxia/HRE-regulated gene therapy for cancer and other diseases. Investigators have studied herpes simplex virus thymidine kinase (HSV-TK), 32 bacterial nitroreductase, 33 proapoptotic protein Bax, 20 and bacterial CD 30 for cancer as well as antiapoptotic protein Bcl2 for ischemic brain damage. 34 In our previous studies, we investigated the effect of HRE copy number on gene expression under hypoxia. Multiple copies of HREs (from 2 to 9) were inserted in front of an enhancerless SV40 early promoter of a mammalian expression vector, and the expression of b-galactosidase was compared in U-87 MG cells. A vector containing nine copies of HRE yielded a 37-fold increase in expression under anoxic conditions and about 17-fold increase under 0.3-1% oxygen levels when compared to expression under normoxic conditions. 7 In the present study, we constructed the vector pH9YCD2 containing a yeast CD gene driven by nine copies of the HRE sequence from erythropoietin and an SV40 early promoter. Western blots demonstrated that human glioblastoma cells transiently or stably transfected with pH9YCD2 strongly expressed CD under hypoxia, whereas the expression under normoxic condition was barely detectable. This conditional expression is an essential requirement for a hypoxia-regulated gene therapy strategy, because strong CD expression will be required in hypoxic tumor tissue, but should not be present in normoxic normal cells. We further confirmed that pH9YCD2-expressed CD retained biological activity, as measured by a 5-FC/5-FU-radioactive conversion assay. The result indicated that pH9YCD2-expressed yeast CD is efficient in converting 5-FC to 5-FU. We also showed that 5-FC is relatively nontoxic to U-87 MG cells, whereas 5-FU is efficient in killing these cells. From these results, we expect that the relatively noncytotoxic 5-FC can be efficiently converted to cytotoxic 5-FU within the hypoxic microenvironment in tumors.
In the cell viability assay (Fig 4) , 74% of the pH9YCD2-transfected glioblastoma cells were killed under hypoxic conditions. Under normoxia, pH9YCD2 produced less toxicity and killed only 40% of the cells as compared with 82% cell killing by pZYCD, a CD expression vector that lacks HRE, demonstrating that pH9YCD2 is much less toxic in normoxic cells. This feature of oxygen tension-dependent cell killing may enable pH9YCD2 to produce a more efficient therapeutic effect than a suicide gene that kills both oxic and hypoxic cells, because it may be possible to use longer treatment courses and higher prodrug doses. Preferential cell killing under hypoxia was also obtained with pH9YCD2 stably transfected U-87 MG cells using the CFE assay, which is recognized as a gold standard for determining cytotoxicity of physical (e.g. radiation) and chemical agents. 35 Thus, two different viability assays provided reproducible evidence that pH9YCD2 preferentially kills hypoxic human glioblastoma cells.
Gene therapy approaches appear to transduce only a portion of tumor cells by current gene delivery techniques. Therefore, it is crucial that the transduced cells are also able to kill surrounding cells that are not transduced (the bystander effect). It has been reported that compared to the HSV-TK/GCV strategy, the bystander effect resulting from treatment with CD/5-FC does not depend on gap junction intercellular communication, rather the bystander effect appears to be determined chiefly by diffusion of 5-FC into the extracellular space. 36 Thus, the CD/5-FC approach may be superior to the HSV-TK/GCV approach for gene therapy. Since our goal is to develop a gene therapy for human brain tumors, we were interested in whether pH9YCD2 could produce a bystander effect in human glioblastoma cells. The data clearly show that this is the case.
The cell viability and CFE assays revealed a small toxic response in pH9YCD2-transfected cells under normoxic conditions. The observed toxicity might have been caused by a small amount of CD production under these conditions that was induced by low levels of constitutive HIF-1a. It is not known whether the amount of gene expression produced under normoxic conditions would significantly impact on the efficacy of this construct in vivo. Therefore, further evaluation of the copy number of HREs, types of promoter, and treatment effects in vitro versus in vivo will be required to better understand this type of gene therapy and its possible application to humans.
In conclusion, we have successfully constructed a hypoxia-regulated yeast CD vector, which is preferentially expressed at high ratios in hypoxic cells to produce biologically active enzyme. The vector-mediated 5-FC Gene-directed prodrug cancer therapy D Wang et al treatment shows potent cytotoxicity and a significant bystander effect in human glioblastoma cells in vitro in a hypoxia-dependent manner. We are presently packaging this vector into a viral delivery system for evaluation in vivo.
Materials and methods
Gene construct
The entire coding sequence of yeast CD, 37 including the translation initiation sequence ACCGCC (Kozak sequence 38 ) and the flanking restriction sites HindIII and NdeI, was generated by PCR. The PCR product was introduced into the pbgal-promoter mammalian expression vector (Clontech, CA) by replacing b-galactosidase at the HindIII and NdeI sites. For generating the HRE enhancer, we chose a 3 0 enhancer region sequence (GCCCTACGTGCTGTCTCACACAGCCTGTC) from the erythropoietin (Epo) gene. 39 Three paired synthetic oligonucleotides, each containing three copies (3XHRE) of the HRE sequence, were inserted in tandem into the multiple cloning site in front of an enhancer-less SV40 early promoter of the pbgal-promoter vector (Fig 7) . Thus, the resulting CD construct, pH9YCD2, contains a concatamer of nine copies of Epo HRE. A yeast CD expression vector without the HRE enhancer, pZYCD, 26 was used as a positive control vector. A bÀgalactosidase vector (pH9LacZ) containing the same HRE and promoter as used in pH9YCD2 was used as a negative control vector.
Cell culture
Human glioblastoma cell line U-87 MG was obtained from the University of California at San Francisco Neurological Surgery Tissue Bank and maintained in Eagles minimum essential medium (EMEM) supplemented with 1% nonessential amino acids and 10% fetal bovine serum. U-87 MG clones stably transfected with pH9YCD2 were maintained in this same medium supplemented with 500 mg/ml G418. For normoxic culture, cells were incubated in a humidified atmosphere containing 5% CO 2 at 371C; for hypoxic culture, cells were incubated in a Billupus-Rothenberg incubation chamber that contained a mixture of 0.3% O 2 , 5% CO 2 , and 94.7% N 2 at 371C.
Transient and stable transfection of U-87 MG cells
U-87 MG cells in six-well plates were transfected with pH9YCD2 using Lipofectamine Plus (Invitrogen, Carlsbad, CA) following the manufacturer's instructions. For stable transfection, cells were cotransfected with pCI neomammalian expression vector, which contains a neomycin phosphotransferase selectable marker (Promega, Madison, WI), and clones were selected in EMEM containing 500 mg/ml G418.
Western blots
pH9YCD2-transfected cells were incubated under normoxic or hypoxic conditions for 16 hours, then scraped from the culture plates, briefly centrifuged, and solubilized into lysis buffer (PBS, 1% nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecylsufate, l mM phenylmethylsulfonyl fluoride, 1 mg/ml aprotinin and 5 mg/ml leupeptin). Equal amounts of protein from the lysates were fractionated on 8-16% polyacrylamide gradient gels and then transferred to Hybond-P membranes (Amersham Life Science, Arlington Heights, IL). Western blots were probed with a rabbit antiserum (1:5,000) directed against yeast CD (custom-made by BabCO, Richmond, CA) and then, after washing, incubated with a horse anti-rabbit IgG antibody conjugated to horseradish peroxidase (1:5,000, Vector Laboratory, Burlingame, CA). The SuperSignal chemiluminescent detection system (Pierce Inc., Rockford, IL) was used for protein detection.
CD activity assay
CD activity was determined by evaluating the percentage of conversion of 5-FC to 5-FU as described by Erbs et al 40 with minor modification. Briefly, subconfluent transiently or stably transfected cells were solubilized in 6-well plates with 60 ml of lysis buffer (100 mM Tris-HCl, pH 7.5, 50 mM ethylenediamine tetraacetic acid, 1% Triton 100, and 1 mM dithiothreitol). Cell lysate (10 ml) was incubated with 5 ml of reaction buffer containing 100 mM Tris-HCl at pH 7.5, 0.03 mCi/ml 5-FC-6-3 H, and 3 mM unlabeled 5-FC (Sigma, St Louis, CA). After incubation at 371C for 1 hour, 3 ml of the sample was fractionated using a thinlayer chromatography plate (TJ Backer, Phillipsburg, NJ) with a mixture of 1-butanol (86%) and water (14%). The 5-FC and 5-FU spots were cut out under UV illumination, and radioactivity was assayed using a liquid scintillation counter (Beckman, Fullerton, CA). The conversion rate was determined by the following equation: cpm of Gene-directed prodrug cancer therapy D Wang et al Colony-forming efficiency assay CFE was performed as described previously. 20 U-87 MG clones stably transfected with pH9YCD2 (named Y87-1 and Y87-2) were seeded into T25 flasks and incubated with various concentrations of 5-FC under hypoxia or normoxia for 48 or 72 hours. On the day before seeding treated cells into six-well plates for CFE assay, SF-126 cells (human glioblastoma) were irradiated with 50 Gy and plated into six-well plates at a density of 5 Â 10 4 cells/ well to serve as a feeder layer. On the following day, test cells were seeded for clonogenic survival. Briefly, cells were trypsinized with 0.05% trypsin, counted, and plated into wells containing the irradiated feeder layer. Plates were then incubated for 14 days. The colonies were stained with methylene blue (0.66% solution in 95% ethanol), and colonies containing at least 50 cells were counted. Plating efficiency (PE) was calculated as the ratio of the number of colonies formed to the number of cells seeded following the statistical approach described by Gupta et al. 35 Surviving fractions were calculated as the PE of treated cells divided by the PE of untreated cells.
Bystander effect assay
CD stably transfected cells Y87-1 and parent cells U-87 MG were mixed at different percentages, treated with 500 mM of 5-FC and incubated for 9 days including an initial hypoxic incubation (0, 24 or 48 hours) before being assayed with the fluorescence-based Titer-Bluet cell viability assay. Expected values represent the killing effect without a bystander effect.
